Amryt Pharma Plc
(NASDAQ : AMYT)

( )
AMYT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.74%178.190.7%$1350.94m
MRKMerck & Co., Inc. 0.21%92.610.7%$1211.55m
PFEPfizer Inc. -1.20%51.680.9%$1096.02m
LLYEli Lilly & Co. 0.74%327.131.1%$1026.00m
BMYBristol-Myers Squibb Co. -1.13%75.971.0%$991.64m
ABBVAbbVie, Inc. 0.03%153.851.9%$959.73m
AZNAstraZeneca Plc -0.67%65.511.0%$470.96m
SGENSeagen Inc. -1.85%176.775.7%$326.06m
GSKGSK Plc -1.01%43.310.2%$272.45m
TPTXTurning Point Therapeutics, Inc. 0.05%75.150.0%$199.28m
HZNPHorizon Therapeutics Plc 2.38%82.765.4%$174.09m
NVSNovartis AG -0.11%84.270.2%$172.25m
MRTXMirati Therapeutics, Inc. 1.10%71.961.6%$150.81m
ALNYAlnylam Pharmaceuticals, Inc. 1.67%150.738.1%$150.31m
NVONovo Nordisk A/S -0.40%111.190.1%$148.30m

Company Profile

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.